In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Lipitor, Detrol Removed From Florida Medicaid Preferred Drug List

Executive Summary

Florida Medicaid recipients will have to try at least two other drugs in the same category before they are allowed to receive any of six Pfizer drugs recently removed from the state's preferred drug list

You may also be interested in...



After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13

After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13

Merck Wins Part D Cholesterol Therapy Formulary Battle; Lipitor In Retreat?

Merck appears to be the big winner in the Medicare Part D formulary placement battle for cholesterol-lowering therapies, according to an analysis of plan formularies conducted by the "The Pink Sheet."

Related Content

Topics

UsernamePublicRestriction

Register

PS046495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel